Claims for vitamin E in angina pectoris have not been based on controlled observations. Even some negative 'eports have not been adequately controlled as to nonspecific factors. Hence, this study of the effects of alpha tocopherol on cardiac pain used a method of investigation carefully Controlled as to psychologic factors which might affect the patient's response oi the examiner's interpretation of results. The dose of synthetic alpha tocopherol acetate (300 mg. by mouth daily for two oI' more months) was the same as that recomnmended by advocates of this form of therapy as optimum in most cases. The results failed to indicate that the vitamin possessed any advantage ove' the pllacebo for treatment of either effo't angina oi mixed types of cardiac and somatic chest pain. DTRING the course of our studies on the visceral and somatic components of chest pain in patients with heart (lisease, 1-4 Vogelsang, Shute and Shute5-9 and ilolotchick'0 reported beneficial effects of vitamin E on "anginal pain" and heart disease. It occurred to us that the relief of pain in such cases might be due, at least in part, to effects of vitamin E on the voluntary muscles rather than on the heart. This concept was supported by the fact that animals deprived of vitamin E show reversible changes in both cardiac'" 12 and skeletal"3 14 musculature, and by reports on the usefulness of vitamin E in the muscular dvstrophies and somatic pain syndromes such as filbromyositis. [5] [6][7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] We decided, therefore, to classify chest pain in our cardiac patients according to visceral and somatic components, and to evaluate by the blind-test method the effect of alpha tocopherol on these components in parallel series of control and treated subjects. The need for such a blind-test study is emphasized by Vogelsang, Shute and Shute themselves,9 as well as by recent editorial comment.'9 The latter conclhdes: "Subjective benefits claimed [for vitamin E] may justify a series of well controlled experimental studies in human heart disease
Claims for vitamin E in angina pectoris have not been based on controlled observations. Even some negative 'eports have not been adequately controlled as to nonspecific factors. Hence, this study of the effects of alpha tocopherol on cardiac pain used a method of investigation carefully Controlled as to psychologic factors which might affect the patient's response oi the examiner's interpretation of results. The dose of synthetic alpha tocopherol acetate (300 mg. by mouth daily for two oI' more months) was the same as that recomnmended by advocates of this form of therapy as optimum in most cases. The results failed to indicate that the vitamin possessed any advantage ove' the pllacebo for treatment of either effo't angina oi mixed types of cardiac and somatic chest pain. DTRING the course of our studies on the visceral and somatic components of chest pain in patients with heart (lisease, [1] [2] [3] [4] Vogelsang, Shute and Shute5-9 and ilolotchick'0 reported beneficial effects of vitamin E on "anginal pain" and heart disease. It occurred to us that the relief of pain in such cases might be due, at least in part, to effects of vitamin E on the voluntary muscles rather than on the heart. This concept was supported by the fact that animals deprived of vitamin E show reversible changes in both cardiac'" 12 and skeletal"3 14 musculature, and by reports on the usefulness of vitamin E in the muscular dvstrophies and somatic pain syndromes such as filbromyositis. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] We decided, therefore, to classify chest pain in our cardiac patients according to visceral and somatic components, and to evaluate by the blind-test method the effect of alpha tocopherol on these components in parallel series of control and treated subjects. The MIET THO)DS Forty-one ambulatory paltieats with c(ionic (bhest pain and with arteriosclerotic and/or hypertensive heart disease were selected at ran(lom from the Cardiac Clinic. Three patients refused to continue their medication after varying periods of time and are discussed later. Thirty-eight patients completed the course of therapy, 19 having received synthetic alpha tocopherol and 19 a matching placebo tablet.
The study was conducted according to stringent blind-test methods. After preliminary study the patients were paired and matched with respect to sex, age, cardiovascular status, (luration and type of chest pain, and other pertinent factors (table 1).
One of each pair w-as allotted by chance to either the control (placebo) or treated (vitamin) group. It may be seen from table 1 that the two groups are closely comparable. None of the examiners knew whether vitamin orI placebo was being a(lministere(l to any l)aiticular patient. The physician (S.H.R.) vho administered the medication never examined the patients. Even in the analysis of the data the final evaluation of the effect of medication was made in each case without knowledge as to whether the patient was in the treated or control group.
These 38 patients exhibited three types of (hest pain: (1) effort angina pain in any part of the chest regularly induced by walking and promptly relieved by rest and/or nitrites (14 treated, 13 control); (2) constant chest paini prain plesent most of the time to a greater or lesser degree (2 treated, 1 control); and (3) intermittent chest pain unlike effort angina (2 treated, 2 control). We regard the chest pain in the first group as being primarily of cardiac origin and in the latter two groups as being chiefly somatic. Two patients had both effort angina and constant pain (both control). During the preliminary period of observation, two patients with effort angina became free of their chest pain a few days before medication was begun (1 treated, 1 control). We kept these patients in the study in order to note whether pain recurred while on medication; in neither instance, however, was there recurrence of chest pain.
None of the patients had pain on breathing, such as characterizes pleurisy or intercostal neuralgia, nor was the pain traceable to any pulmonary lesion.
To evaluate effects on the somatic factor of cardiac pain, at each visit the presence and location of tender areas in the chest muscles were noted on special charts, together wvith a description of pain reference induced by pressure on specific trigger areas.2 Areas of spontaneous pain, whether constant or related to effort, were also mapped. The muscles examined included the sternalis, pectoralis major and minor, serratus anterior, erector spinae (especially the multifidus and iliocostalis), and other scapular and interscapular muscles. These examinations were repeated at each visit, usually every two or three weeks. A total of 365 visits were made by the 41 patients, exclusive of those for laboratory tests.
Initial laboratory work included electrocardiorgams, x-ray examinations of the heart and spine, complete blood counts, urinalysis, blood chemistry, and determination of blood sedimentation rates. The electrocardiograms were repeated at intervals during the study, and other tests as indicated. Special tests included the following: 1. Measurement of the patient's capacity for effort without pain, or exercise tolerance. At intervals of several weeks this test was carried out according to the two-step technic under standard conditions previously described. 25 26 In 9 patients the results of the test were inconclusive because of indecisive end points. On 13 patients the test could not be performed because pain on effort was not present, or because pain in the joints of the lower extremities prevented walking over steps, or because of intermittent claudication.
Measurement of skeletal muscle power. A
spring-device grip recorder, standardized in arbitrary units, was used to measure the strength of the grip in each hand.
3. Measurement of skeletal muscle endurance. Deep pain was produced by contraction of the forearm muscles during ischemia by a technic similar to that of Lewis, 27 Harrison and BigeloW,28 and others. The pressure in the cuff was raised to a minimum of 200 mm. Hg, or if the systolic blood pressure was more than 150 mm., to 50 mm. above this. A metronome, Set for one beat per second, was used to maintain a constant rate of thirty flexor contractions per minute. On alternate beats, the patients closed and opened the fingers; the two movements were recorded as a unit by a mechanical counter. The patient stopped when there was so much pain that he could no longer keep up with the metronome. The end point was usually quite sharp: sudden inability to move the fingers on account of pain.
The plan of medication was as follows: Alpha tocopherol was given in doses of 200 mg. daily by mouth for two weeks, and then 300 mg. daily. This was administered in divided doses of 100 mg. each. (49-72) 6.1 yrs. (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) 15 (79%) 4 (22%) 6 (32%) 9 (47%) 8 (42%) 0 (0%) 12 
A similar number of the matching placebo tablets was prescribed. For the 38 patients in the final series, administration of alpha tocopherol averaged sixteen weeks (ten to twenty weeks), and of the placebo 16.6 weeks (ten to twenty weeks). Tne 3 patients of the original series who discontinued medication (alpha tocopherol), stopped the drug because of increased chest pain in one, two, and five weeks, respectively. Use of iron salts and mineral oil was prohibited because it has been suggested that these substances might interfere with the absorption of alpha tocopherol. ' 9. 29 Nitroglycerine and digitalis, if in use, were continued as before. RESULTS * Chest Pain. It may be seen from table 2 that the response to medication was essentially the same for alpha tocopherol and for the placebo. Thus, no improvement was noted in 63 per cent of the 19 treated subjects and in 73 per cent of the 19 controls. Subjective improvement was reported by 37 per cent of the treated patients and by 27 per cent of the controls. Two of the control subjects who were classed as unimproved had intercurrent clinical complica- tient with the infaretion, and these changes were related to this acute episode. When the effect of medication was analyzed with respect to visceral and somatic components of chest pain, it was found that the re- 
* Two patients appear twice ill this analysis since they have both effort angina and constant chest pain. The two patients who became free of chest pain just before start of medication are excluded. tions one patient developed congestive heart failure and the other, an acute myocardial infarction. These complications occur naturally in the course of arteriosclerotic heart disease, and in so small a series it cannot be considered statistically significant that both of these patients were in the control group. It may be noted that the only changes observed in the serial electrocardiograms occurred in the pa-* A preliminary report has been made.30 sults were again similar in the treated and control groups (table 3) . In 2 patients, trigger areas present in the chest muscles on the initial examination disappeared during medication (1 treated, 1 control). Five patients who were without such areas of deep tenderness at the start, remained so. In all other patients, the same tender areas in the better as the result of alpha tocopherol medication (table 5) . It should be noted that the improvement is a matter of degree, rather than total relief of pain. The majority of these did not show a corresponding improvement in exercise tolerance. Furthermore, the patients on placebo medication who said they were much better (table 6) made exactly the same kind of statements regarding relief of pain as did those on alpha tocopherol. This indicates the need for parallel series. In fact, one patient expended his supply of the placebo tablets two days before his final visit and stated that his chest pain became much worse in those two days.
Skeletal Muscle. Objective evidence of improvement in this function was also lacking. The measurements of grip, that is, muscle strength, showed a net change after medication of -5 per cent for the treated, and +2 per cent for the control group (table 7) . Similarly, with respect to skeletal muscle endurance or capacity for work during ischemia, the net change after medication is similar for the vita- +25% (-36% to +100%) average net increase of 6 per cent in exercise tolerance for the treated group, and 110 per cent for the control group. This average value of 110 per cent includes one patient in the control group who had a very large percentage increase in exercise tolerance (633 per cent). This patient had had an acute myocardial infarction six months prior to the initial exercise tolerance test, and it is likely that the final test five months later reflects spontaneous improvement in myocardial function during recovery from this acute episode.
Seven patients said that they were much mi-treated and the placebo-treated subjects.
The increase of 14 per cent and 25 per cent for treated and control groups, respectively, may be due to training. Hypertension. It has been recommended that doses of only 150 mg. of alpha tocopherol be given initially to patients with hypertension because larger doses raise the blood pressure.9
Our data show that the blood pressure was not elevated by 200 mg. and 300 mg. doses of alpha tocopherol, even in the 2 patients with systolic blood pressure levels of 210 and 220 mm. Hg respectively. Furthermore, in none of the 6 pa-tients with hypertensive heart disease who received alpha tocopherol, was there any significant lowering of the blood pressure.
Toxicity. No toxic effects were attributable to these doses of alpha tocopherol. The 3 patients who insisted on discontinuing the vitamin therapy because of increased pain were subject to spontaneous exacerbations of chest pain prior to this medication. Other complaints during vitamin administration were palpitation, spots before the left eye, and sleepiness. On the other hand, 3 patients who received the placebo blamed it for causing nausea, constipation, and weakness, respectively.
DISCUSSION
Evaluation of drug therapy in cardiac pain is fraught with pitfalls due to the many nonspecific factors that may contribute to relief of pain in this condition.4 It is because of this that we took care to establish a control group as similar as possible to the treated group (table  1) , and to conduct the study under doubly blind conditions. Not only were the patients unaware of the nature of the agent being administered, but also those who examined the patients and evaluated the results were ignorant of the material given in any particular case.
As we have indicated, the response to alpha tocopherol was essentially the same as that to the placebo, namely, subjective relief of pain in 37 per cent and 27 per cent, respectively (table 2). These figures are in accord with the observations of Evans and Hoyle3l that the administration of a placebo to patients with angina pectoris was accompanied by a diminution of pain in 40 per cent of the cases.
Our results fail to confirm those of Shute, Shute, and Vogelsang6 who reported some degree of improvement in 96 per cent of 84 patients with "anginal pain" on daily doses of about 200 mg. to 300 mg. of alpha tocopherol; o of their patients received 400 mg. and one, 600 mg. daily. They regard a dose of 200 mg. as optimum in 80 per cent of cardiac cases.9
As for the speed of effects, they state9 "A favorable response to tocopherol therapy may begin at once, but oftener does not appear for 5 to 10 days." They noted that occasionally a therapeutic result may not appear for as long as six weeks. According to these criteria, the periods of about two and one-half to five months, during which our patients received "optimum" doses of alpha tocopherol, represent adequate time for clinical trial.
Failure of alpha tocopherol to relieve angina pectoris has likewise been reported by others. Ravin and Katz20 gave the equivalent of 250 mg. of alpha tocopherol daily to 11 patients with effort angina for an average of fourteen weeks (four to twenty-four weeks). Levy and Boas21 administered 200 mg. to 800 mg. of alpha tocopherol daily to a similar group of 8 patients for from three to twelve weeks. Baer, Heine, and Gelfond22 employed a daily dose of 300 mg. to 400 mg. of vitamin E in 5 such patients. Makinson, Olesky, and Stone23 gave 150 mg. daily of vitamin E to patients with angina pectoris for three weeks. None of these investigators found unequivocal improvement in cardiac pain. Ball24 gave 300 mg. of alpha tocopherol daily to 10 such patients for at least six weeks, and observed some diminution of pain in 4, but noted that this effect was comparable to the 40 per cent improvement which follows administration of a placebo to patients with angina pectoris. SUMMARY AND CONCLUSIONS 1. Effects of synthetic alpha tocopherol and a placebo were compared by the blind-test method in 41 ambulatory patients with chronic chest pain and heart disease (chiefly arteriosclerotic and hypertensive). Thirty-eight patients completed the course of medication; 1]9 received the vitamin, and 19 the placebo.
2. Most of the patients (76 per cent) had effort angina alone; the remainder exhibited mixed types of cardiac and somatic chest pain.
3. Synthetic alpha tocopherol was given by mouth in daily doses of 200 mg. for about two weeks, and 300 mg. thereafter. A similar number of matching placebo tablets was given.
4. The average duration of administration of the vitamin was sixteen weeks (ten to twenty weeks) and of the placebo, 16 .6 weeks (ten to twenty weeks). 5. No toxic effects of these doses of alpha tocopherol were noted. 6. The effects of medication on chest pain and on objective measurements of cardiac and skeletal muscle function were similar for the group given alpha tocopherol and for the controls who received the placebo. 7. Our results fail to confirm the reported benefits of alpha tocopherol in cardiac pain.
